XT
ANRO icon

XTX Topco’s Alto Neuroscience ANRO Stock Holding History

XTX Topco’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$896K Buy
39,841
+19,017
+91% +$352K 0.02% 1507
2025
Q4 		$371K Buy
20,824
+5,078
+32% +$63.9K 0.01% 1879
2025
Q3 		$63.3K Buy
+15,746
New +$52.2K ﹤0.01% 2123

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco's ANRO Position: Q1 2026 in Review

XTX Topco increased its Alto Neuroscience (ANRO) stake by 91% in Q1 2026, buying an estimated $352K and bringing the position to 39,841 shares worth $896K. The position accounts for 0.02% of the portfolio, ranked #1507.

XTX Topco first reported a position in ANRO in Q3 2025 and has held it in 3 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • XTX Topco held 39,841 shares of Alto Neuroscience worth $896K as of Q1 2026.
  • XTX Topco bought 19,017 Alto Neuroscience shares in Q1 2026, an estimated $352K.
  • Alto Neuroscience made up 0.02% of XTX Topco's portfolio in Q1 2026, its #1507 holding.
  • XTX Topco first reported a position in Alto Neuroscience in Q3 2025 and has held it in 3 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.